Valeant Pharmaceuticals: An Executive’s Exit Fuels Worries

And the hits just keep on coming for Valeant Pharmaceuticals (VRX). Just days after CEO Mike Pearson returns from a long illness, the drug maker abruptly announces last night that Deb Jorn, head of the U.S. gastrointestinal and dermatology divisions, resigned effective immediately. Valeant is already being battered by political rhetoric regarding drug prices and […]